http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2727792-C
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6447f33e84f7450705d85e3c80657c02 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-125 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-15 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-125 |
| filingDate | 2008-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d63d8c55f02f2514c438a031b5e89c5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ef5e2380ffe1be2ead64458531a8bb8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99d15dd325edd827614de88e582e0e5c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1dff48fec7a3d4413414701e63807f96 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_860a31a75a7c499a9f153acb0d2fc97f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_729acb006e5322e523c461a4508b4133 |
| publicationDate | 2017-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2727792-C |
| titleOfInvention | Antitumoral terpenoid pharmaceutical composition abisilin exhibiting angiogenesis-inhibiting action |
| abstract | The invention relates to medicine and the chemical and pharmaceutical industry and to agents for treating diseases caused by angiogenesis regulation disorders, in particular to a method for treating oncological diseases of different genesis by inducing angiogenesis inhibition which is secondary to the direct antitumoral, anti-reccurant and anti-metastatic action as well as by the associated activation of the apoptosis endogenous system. The invention uses a novel peroral medicinal form 'Abisilin', comprising ingredients relating to the class of natural terpene compounds (isoprenoids), produced from coniferous threes of a Pinaceae family, which medicinal form contains: sesquiterpenoids (3-6%), neutral diterpenoids (11-15%), diterpene acids (22-28%), triterpene acids (8-16%), unsaturated and saturated fatty acids (0.1-0.3%), phenolic compounds (0.1-0.2%), monoterpenoids being the rest, wherein the bornyl acetate content is equal to not less that 10.0% of the total terpene composition. It is expected that the use of the novel peroral medicinal form 'Abisilin', the substance of which exhibits immunomodulating, antibacterial, antiinflammatory, anesthetic, wound-healing and other pharmacologically-significant actions, is free of contra-indications and toxic effects and can be used together with different agents, provides a novel therapeutic approach and enhances the efficiency of treatment of oncological and many other diseases caused by angiogenesis process disorders. |
| priorityDate | 2008-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 172.